Ovarian Cancer

Mirvetuximab soravtansine induced confirmed objective response in about one-third of women with folate receptor alpha-high platinum-resistant ovarian cancer who previously received bevacizumab, according to the agent’s manufacturer.

The FDA approved the imaging drug pafolacianine to help surgeons identify ovarian cancer lesions.

Increased use of neoadjuvant chemotherapy appeared associated with improvements in short-term mortality without sacrificing long-term survival in ovarian cancer, according to a comparative effectiveness research study in JAMA Oncology.

The FDA granted fast track designation to nemvaleukin alfa as part of combination therapy for treatment of platinum-resistant ovarian cancer, according to the agent’s manufacturer.

New data have linked next-generation sequencing with improved overall survival in ovarian cancer, according to a presenter at the virtual ASCO Annual Meeting.

Even among insured patients, germline BRCA testing is underutilized in women with newly diagnosed ovarian cancer, according to a study presented at the virtual ASCO Annual Meeting.

More than a third of patients with solid tumors showed evidence of antitumor response after treatment with ADP-A2M4CD8, according to data presented at the virtual ESMO Congress.

The FDA cleared an investigational new drug application for a T-cell receptor therapy designed to treat adults with solid epithelial cancers that express Kita-Kyushu lung cancer antigen 1.

The FDA cleared an investigational new drug application for a chimeric antigen receptor T-cell therapy designed to treat women with relapsed epithelial ovarian cancer.

The FDA granted fast track designation to IN10018 for treatment of platinum-resistant ovarian cancer.